|
|
|
@ -48,4 +48,5 @@ date:: [[2023/12]]
|
|
|
|
- January: Draft primary and secondary research questions aligned to government/programme decision requirements
|
|
|
|
- January: Draft primary and secondary research questions aligned to government/programme decision requirements
|
|
|
|
- Full draft protocol Q1 2024 (after formative research)
|
|
|
|
- Full draft protocol Q1 2024 (after formative research)
|
|
|
|
- 3 dose regimen
|
|
|
|
- 3 dose regimen
|
|
|
|
- Continue to include – potential to inform future MDA degi
|
|
|
|
- Continue to include – potential to inform future MDA design and improved effectiveness/cost effectiveness of MDAs, improved clinical management
|
|
|
|
|
|
|
|
- Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement
|
Borja Robert
12 months ago